About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NVO · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Bod…
NCT07931599 · Diabetes Mellitus, Type 2
Zenagamtide, Semaglutide
NVO
Novo Nordisk A/S
Phase 3Not yet recruiting1,060Jul 24, 2028Registry ↗
Nov 12, 2026AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood…
NCT07931573 · Type 2 Diabetes
Zenagamtide, Semaglutide
NVO
Novo Nordisk A/S
Phase 3Not yet recruiting1,200Jul 4, 2028Registry ↗
Nov 12, 2026A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to…
NCT07931547 · Type 2 Diabetes, Chronic Kidney Disease
Placebo, Zenagamtide
NVO
Novo Nordisk A/S
Phase 3Not yet recruiting450Jul 31, 2028Registry ↗
Nov 12, 2026A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to…
NCT07931495 · Diabetes Mellitus, Type 2
Zenagamtide, Placebo
NVO
Novo Nordisk A/S
Phase 3Not yet recruiting200Jun 5, 2028Registry ↗
Nov 10, 2026A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Partici…
NCT07896109 · Diabetes Mellitus, Type 2
NNC9836-0001, Placebo (NaCl)
NVO
Novo Nordisk A/S
Phase 1Recruiting
was not yet recruiting
121Jul 26, 2028Registry ↗
Nov 10, 2026A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it…
NCT07587710 · Overweight, Obesity
NNC0487-0111
NVO
Novo Nordisk A/S
Phase 1Recruiting
was not yet recruiting
35Dec 1, 2027Registry ↗
Nov 10, 2026AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide…
NCT07400107 · Obesity, Overweight
NNC0487-0111, Semaglutide
NVO
Novo Nordisk A/S
Phase 3Active, not recruiting
was not yet recruiting
985Dec 19, 2028Registry ↗
Nov 6, 2026AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess…
NCT07533175 · Diabetes Mellitus, Overweight
NNC0487-0111, Placebo (matched to NNC0487-0111)
NVO
Novo Nordisk A/S
Phase 3Active, not recruiting
was recruiting
638Aug 7, 2028Registry ↗
Nov 5, 2026A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in Peopl…
NCT07919405 · Hypertension, Obesity
CagriSema, Semaglutide
NVO
Novo Nordisk A/S
Phase 3Not yet recruiting1,408Jun 1, 2028Registry ↗
Nov 4, 2026Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney…
NCT04968184 · Chronic Kidney Diseases
Placebo, KBP-5074
NVO
Novo Nordisk A/S
Phase 3Terminated666Jan 30, 2024Registry ↗
Nov 2, 2026Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity a…
NCT04916470 · Heart Failure With Preserved Ejection Fraction (HFpEF) and…
Semaglutide, Placebo (Semaglutide)
NVO
Novo Nordisk A/S
Phase 3Completed617Oct 11, 2023Registry ↗
Oct 28, 2026A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidn…
NCT07900438 · Cardiovascular Risk, Chronic Kidney Disease
Semaglutide
NVO
Novo Nordisk A/S
Phase 4Recruiting300Dec 20, 2029Registry ↗
Oct 28, 2026A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732 · Haemophilia A
Denecimig
NVO
Novo Nordisk A/S
Phase 3Recruiting84Mar 23, 2029Registry ↗
Oct 28, 2026Compassionate Use of Concizumab if You Have Haemophilia
NCT04921956 · Congenital Haemophilia
Concizumab
NVO
Novo Nordisk A/S
—No longer available——Registry ↗
Oct 26, 2026A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People
NCT07829406 · Healthy Volunteers
NNC0642-1895, Placebo
NVO
Novo Nordisk A/S
Phase 1Recruiting148Sep 12, 2027Registry ↗
Oct 26, 2026A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomati…
NCT06859073 · Healthy Volunteers, Hyperuricemia
NNC4004-0002, Placebo
NVO
Novo Nordisk A/S
Phase 1Active, not recruiting50Jan 19, 2027Registry ↗
Oct 22, 2026A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a W…
NCT03811535 · Growth Hormone Deficiency in Children
Somapacitan, Norditropin®
NVO
Novo Nordisk A/S
Phase 3Completed200Nov 10, 2021Registry ↗
Oct 21, 2026CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (…
NCT07207811 · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
NNC6019-0001, Placebo (NNC6019-0001)
NVO
Novo Nordisk A/S
Phase 3Recruiting1,280Jun 29, 2029Registry ↗
Oct 19, 2026Semaglutide Health Outcomes and Patient Adherence in Australia
NCT07881770 · Overweight, Obesity
Semaglutide
NVO
Novo Nordisk A/S
—Not yet recruiting10,000Feb 28, 2028Registry ↗
Oct 19, 2026Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Du…
NCT07607587 · Obesity, Overweight
Cagrilintide, Placebo (matched to Cagrilintide)
NVO
Novo Nordisk A/S
Phase 1Recruiting114Nov 19, 2027Registry ↗
Oct 19, 2026A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo i…
NCT07282613 · Diabetes Mellitus, Type 2
CagriSema (Cagrilintide B and Semaglutide I), Placebo match…
NVO
Novo Nordisk A/S
Phase 3Recruiting80Sep 7, 2029Registry ↗
Oct 19, 2026A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepati…
NCT06534411 · Diabetes Mellitus, Type 2
Cagrilintide, Semaglutide
NVO
Novo Nordisk A/S
Phase 3Completed1,023Jun 2, 2026Registry ↗
Oct 19, 2026A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepati…
NCT06221969 · Type 2 Diabetes
Cagrilintide, Semaglutide
NVO
Novo Nordisk A/S
Phase 3Completed1,024Mar 4, 2026Registry ↗
Oct 16, 2026A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabet…
NCT07868354 · Overweight, Obesity
Tirzepatide, Zenagamtide
NVO
Novo Nordisk A/S
Phase 1Recruiting60Sep 7, 2028Registry ↗
Oct 16, 2026A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabet…
NCT07855133 · Overweight, Obesity
Semaglutide, Zenagamtide
NVO
Novo Nordisk A/S
Phase 1Recruiting60Sep 6, 2028Registry ↗
Oct 13, 2026A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants…
NCT07214870 · Fatty Liver Disease
NNC4005-001, Placebo
NVO
Novo Nordisk A/S
Phase 1Active, not recruiting29May 14, 2027Registry ↗
Oct 13, 2026Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181 · Non-alcoholic Steatohepatitis
Semaglutide, Placebo
NVO
Novo Nordisk A/S
Phase 3Active, not recruiting1,205Apr 25, 2029Registry ↗
Oct 9, 2026A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who…
NCT06260709 · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
NNC6019-0001
NVO
Novo Nordisk A/S
Phase 2Active, not recruiting88Feb 29, 2028Registry ↗
Oct 8, 2026An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medic…
NCT05621746 · Haemophilia A
Esperoct
NVO
Novo Nordisk A/S
—Completed123Apr 30, 2026Registry ↗
Oct 8, 2026French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Synd…
NCT05308927 · Noonan Syndrome
Norditropin
NVO
Novo Nordisk A/S
—Enrolling by invitation221Mar 17, 2028Registry ↗
Oct 8, 2026Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
NCT04682145 · Haemophilia A
Turoctocog alfa pegol
NVO
Novo Nordisk A/S
—Enrolling by invitation50Dec 1, 2026Registry ↗
Oct 8, 2026Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Pa…
NCT03972345 · Growth Hormone Deficiency in Children, Born Small for Gesta…
Norditropin® FlexPro®
NVO
Novo Nordisk A/S
—Enrolling by invitation750Jun 30, 2029Registry ↗
Oct 8, 2026Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
NCT03690336 · Haemophilia B
Nonacog beta pegol
NVO
Novo Nordisk A/S
—Enrolling by invitation10Oct 1, 2027Registry ↗
Oct 7, 2026A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on…
NCT07815067 · Overweight, Obesity
Zenagamtide injection, Zenagamtide tablet
NVO
Novo Nordisk A/S
Phase 1Recruiting320Jun 12, 2028Registry ↗
Oct 7, 2026A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in Peo…
NCT07668388 · Diabetes Mellitus, Type 2
UBT251, UBT251 Placebo
NVO
Novo Nordisk A/S
Phase 2Recruiting300Oct 4, 2027Registry ↗
Oct 7, 2026AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess…
NCT07571109 · Obesity, Overweight
NNC0487-0111, Placebo (matched to NNC0487-0111)
NVO
Novo Nordisk A/S
Phase 3Recruiting300Jun 26, 2028Registry ↗
Oct 7, 2026Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment Wit…
NCT07220759 · Overweight, Obesity
Cagrilintide, Placebo (matched to Cagrilintide)
NVO
Novo Nordisk A/S
Phase 3Active, not recruiting330May 12, 2027Registry ↗
Oct 7, 2026A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose…
NCT05726227 · Obesity
Semaglutide, Placebo
NVO
Novo Nordisk A/S
Phase 3Active, not recruiting212Oct 15, 2025Registry ↗
Oct 7, 2026A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in Peo…
NCT03811561 · Diabetes Mellitus, Type 2
Semaglutide, Placebo (semaglutide)
NVO
Novo Nordisk A/S
Phase 3Active, not recruiting1,500Nov 7, 2027Registry ↗
Oct 6, 2026A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Establish…
NCT07861100 · Cardiovascular Risk, Obesity
Zenagamtide, Placebo
NVO
Novo Nordisk A/S
Phase 3Not yet recruiting8,500Sep 16, 2030Registry ↗
Oct 6, 2026Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Ex…
NCT07653139 · Haemophilia A
No treatment given
NVO
Novo Nordisk A/S
—Enrolling by invitation150Dec 26, 2026Registry ↗
Oct 6, 2026A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week…
NCT03878446 · Short Stature Children Born Small for Gestational Age (SGA)
Somapacitan, Norditropin®
NVO
Novo Nordisk A/S
Phase 2Active, not recruiting62May 5, 2021Registry ↗
Oct 5, 2026A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of…
NCT06979362 · Heart Failure
CDR132L, Placebo
NVO
Novo Nordisk A/S
Phase 2Recruiting200Nov 16, 2027Registry ↗
Oct 2, 2026A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar…
NCT06542874 · Type 2 Diabetes (T2D)
NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous)
NVO
Novo Nordisk A/S
Phase 2Completed448Oct 1, 2025Registry ↗
Oct 1, 2026A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adult…
NCT07757087 · Overweight, Obesity
NNC0487-0111, Placebo
NVO
Novo Nordisk A/S
Phase 1Recruiting120Sep 18, 2028Registry ↗
Oct 1, 2026A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart…
NCT06200207 · Heart Failure, Systemic Inflammation
Ziltivekimab, Placebo
NVO
Novo Nordisk A/S
Phase 3Active, not recruiting673Oct 1, 2026Registry ↗
Oct 1, 2026A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure…
NCT05636176 · Heart Failure
Ziltivekimab, Placebo
NVO
Novo Nordisk A/S
Phase 3Terminated4,874Sep 3, 2026Registry ↗
Sep 30, 2026Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
NCT07850765 · Overweight, Obesity
Semaglutide
NVO
Novo Nordisk A/S
—Completed1,260Aug 31, 2026Registry ↗
Sep 30, 2026Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251 · Diabetes Mellitus, Type 2
CagriSema
NVO
Novo Nordisk A/S
Phase 3Recruiting210Jun 9, 2027Registry ↗
Sep 30, 2026A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People
NCT07797855 · Healthy Volunteers, Cardiometabolic Diseases
NNC0705-0002, Placebo
NVO
Novo Nordisk A/S
Phase 1Recruiting112Aug 1, 2027Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:24 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances